To view presentation slides, please click the individual titles within each session.
Session I: Prevention, Screening, And Genomic Markers
Chair: Alan W. Partin, MD, PhD
Prostate Cancer Screening: What We’ve Learned and Where We Should Go
Gerald L. Andriole, Jr., MD
Early Detection and Family Practice
Matt T. Rosenberg, MD
When to Biopsy: The Role for PSA and Novel Biomarkers
Stacy Loeb, MD
Soy Isoflavones in Prostate Cancer Prevention, Treatment and Survivorship
Omer Kucuk, MD
What Are Currently the Best Decision Markers for Biopsy and Re-Biopsy of the Prostate?
E. David Crawford, MD
Progress in Prostate Cancer Grading
M. Scott Lucia, MD
Targeted Prostate Cancer Screening: Role of Germline Genetic Testing
A. Karim Kader, MD, PhD
Session II: Localized Disease
Chair: James A. Eastham, MD
The Role of Multi-Parametric MRI: Implication and Implementation
Nelson N. Stone, MD
Active Surveillance at Johns Hopkins – Update 2015
Alan W. Partin, MD, PhD
Radical Prostatectomy: Management of Primary From Localized to Oligometastatic Disease
James A. Eastham, MD
Accurate Staging of Prostate Cancer
Phillip J. Koo, MD
Prostate Biopsy and Targeted Therapy
Nelson N. Stone, MD
Strategies of Radiotherapy for Intermediate- to High-risk Prostate Cancer
Daisaku Hirano, MD
Review of Selected Posters
The 4Kscore Test Predicts High Grade Prostate Cancer on Biopsy at PSA Levels < 4ng / mL
Jay R. Newmark, MD
The CCP Score Provides Significant Prognostic Information in Gleason Score ≤ 6 Patients
Michael K. Brawer, MD
Session III: Advanced Disease
Cardiovascular Complications of ADT: Reviewing Preclinical and Clinical Data and Introducing the RADICAL-PC Trial
Jehonathan Pinthus, MD, PhD
Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Annihilation?
Jehonathan Pinthus, MD, PhD
Early Chemotherapy for Metastatic Prostate Cancer
Daniel P. Petrylak, MD
Personalized ADT
Thomas E. Keane, MBBCh
Statins, Aspirin, and Metformin (S.A.M.): The Best “Natural” Pills for Patients Concerned About PCa
Mark A. Moyad, MD, MPH
Session IV: Advanced And Metastatic Disease
Chair: Neal D. Shore, MD
There Are Newer and More Promising Agents Than Chemotherapy
Neal D. Shore, MD
Current and Future Opportunities Combining Radiation with Immunotherapy
Steven E. Finkelstein, MD
Intermittent Therapy: When To Start, or Restart, and the Role of Imaging
Leonard G. Gomella, MD
Session V: Advanced And Castration-Resistant Disease
Chair: Neal D. Shore, MD
Review of Selected Posters
Tracy McGowan, MD
Neal D. Shore, MD
Beyond Drugs and Pumps: A New Approach to the Management of Erectile Dysfunction
Kambiz Tajkarimi, MD
Neal D. Shore, MD
Radiopharmaceuticals: Has There Been Progress?
Neal D. Shore, MD
The Role of the Urologist in the Management of Advanced Prostate Cancer 2016
Raoul S. Concepcion, MD
The Future of Clinical Research in Private Practice: Alive or Dead?
Lawrence I. Karsh, MD
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.
